1610601-59-6

Basic information

• Product Name: 2-(4-chlorophenyl)-5-(3-(4-nitrophenyl)-1-phenyl-1H-pyrazol-4-yl)-1,3,4-oxadiazole
• Synonyms: 2-(4-chlorophenyl)-5-(3-(4-nitrophenyl)-1-phenyl-1H-pyrazol-4-yl)-1,3,4-oxadiazole
• CAS NO: 1610601-59-6
• Molecular Weight: 443.849
• Mol File: 1610601-59-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2-(4-chlorophenyl)-5-(3-(4-nitrophenyl)-1-phenyl-1H-pyrazol-4-yl)-1,3,4-oxadiazole(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-chlorophenyl)-5-(3-(4-nitrophenyl)-1-phenyl-1H-pyrazol-4-yl)-1,3,4-oxadiazole(1610601-59-6)
• EPA Substance Registry System: 2-(4-chlorophenyl)-5-(3-(4-nitrophenyl)-1-phenyl-1H-pyrazol-4-yl)-1,3,4-oxadiazole(1610601-59-6)

Safety Data

• Hazardous Substances Data: 1610601-59-6(Hazardous Substances Data)

Upstream product

• 100-63-0 phenylhydrazine 
• 100-19-6 (4-nitrophenyl)ethanone 
• 77635-72-4 1-(4-nitro-phenyl)-ethanone-phenylhydrazone 
• 1610601-67-6 C₂₃H₁₆ClN₅O₃ 
• 21487-49-0 3-(4-nitrophenyl)-1-phenyl-1H-pyrazole-4-carbaldehyde 
• 536-40-3 4-chlorobenzoic acid hydrazide 
• 1126-46-1 Methyl 4-chlorobenzoate 
• 74-11-3 para-chlorobenzoic acid 

Relevant articles and documents

Design and synthesis of novel 2-phenyl-5-(1,3-diphenyl-1H-pyrazol-4-yl)-1, 3,4-oxadiazoles as selective COX-2 inhibitors with potent anti-inflammatory activity

A novel series of 2-phenyl-5-(1,3-diphenyl-1H-pyrazol-4-yl)-1,3,4- oxadiazoles were designed and synthesized for selective COX-2 inhibition with potent anti-inflammatory activity. Among the compounds tested, 9g (2-(3-(4-nitrophenyl)-1-phenyl-1H-pyrazol-4-yl)-5-phenyl-1,3,4-oxadiazole) was found to be the most potent inhibitor of COX-2 with IC of 0.31 μM showing promising degree of anti-inflammatory activity in the carrageenan-induced rat paw edema model with ED of 74.3 mg/kg. The lead compound 9g further showed suppression of acetic acid-induced writhes comparable to that of aspirin and gastro-sparing profile superior to the aspirin. Molecular docking analysis displayed higher binding affinity of ligands towards COX-2 than COX-1.